Nicotine Science and Policy

Claims about vaping-related cardiovascular harm have been challenged following a study involving just 17 vapers, 19 smokers and 22 non-users.

Although researchers observed differences in blood vessel function and fitness, independent experts highlighted important limitations, including the small sample size, previous smoking history and the inability to establish causation.

The criticism reinforces the need for larger, longer-term studies and careful interpretation of findings. Accurate tobacco harm reduction research must distinguish potential health risks from demonstrated harm without overlooking the broader evidence on switching away from cigarettes.

Eight mouse studies examining children's potential exposure to residual vaping aerosol have raised questions about the reliability of experimental models used in nicotine research.

A detailed methodological review identifies unusually high aerosol concentrations, outdated devices and exposure conditions that may not reflect everyday environments. These limitations complicate the interpretation of laboratory findings and their relevance to human health.

The analysis highlights the importance of realistic exposure assessment and scientific rigour, particularly when animal studies are used to inform public health messaging and tobacco harm reduction policy.

US cigarette sales are declining two to three times faster than their historical trend, raising questions about the future of tobacco control as smoking becomes less common.

Despite this progress, cigarette taxes and legal settlement payments remain important sources of state revenue, while only a small proportion is allocated to smoking prevention and cessation programmes.

These financial arrangements raise concerns about potential unintended incentives in tobacco policy. Public health priorities should remain focused on reducing smoking-related deaths, supporting cessation and ensuring access to lower-risk nicotine alternatives.

Regulatory uncertainty is placing increasing pressure on independent vaping businesses across the United States. Restrictions affecting shipping, payment processing and online sales are creating significant operational challenges for companies serving adult smokers.

An industry veteran with 18 years of experience describes these pressures as part of a broader effort by major tobacco companies to undermine independent competitors.

The concerns raise important questions about market competition and tobacco harm reduction. Clear, workable regulation is essential to supporting responsible businesses and preserving access to lower-risk alternatives for adults seeking to quit smoking.

Australia's illicit nicotine market has expanded to include nicotine replacement products, with authorities seizing more than 650,000 pieces of unapproved nicotine gum in Brisbane.

The products were suspected of being counterfeit and contained potentially high nicotine doses, raising concerns about consumer safety. Their discovery also brings attention to the affordability of approved nicotine replacement therapies and the demand for accessible alternatives to cigarettes.

The case highlights the importance of combining effective enforcement with affordable, quality-controlled nicotine products. Tobacco harm reduction depends on ensuring that safer options remain more accessible and trustworthy than illicit supplies.